EligibleTrials

Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation

Recruiting · NCT07654179 · Interventional (participants receive a specific treatment) · Lead sponsor: Riphah International University

View the official record on ClinicalTrials.gov →
ObesityDepression

Interventions studied

Antidepressant TherapyMetformin

What this trial is about

The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.

Who can take part

Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

4 locations listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.